Wanbury Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

Wanbury announced the company has expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APIs).

For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore.

The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs.

Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.

Net profit of Wanbury rose 7.11% to Rs 21.70 crore in the quarter ended March 2026 as against Rs 20.26 crore during the previous quarter ended March 2025. Sales declined 4.31% to Rs 164.58 crore in the quarter ended March 2026 as against Rs 172.00 crore during the previous quarter ended March 2025.

For the full year,net profit rose 116.61% to Rs 66.13 crore in the year ended March 2026 as against Rs 30.53 crore during the previous year ended March 2025. Sales rose 8.47% to Rs 650.27 crore in the year ended March 2026 as against Rs 599.51 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Wanbury will hold a meeting of the Board of Directors of the Company on 14 May 2026.

The launch comes in response to recent Drug Controller General of India restrictions on fixed-dose cold combinations for children under four years. The move strengthens Wanbury?s Coriminic brand and positions the company to capture a larger share of the pediatric cold care market.

The new drops provide targeted relief from allergic symptoms such as severe cold, blocked nose, and sneezing, while aligning with regulatory safety guidelines.

The company is also expanding the Coriminic range with Coriminic NS (Normal Saline) Nasal Drops, a non-systemic nasal decongestant designed to provide localised relief from nasal congestion in children. These launches aim to help physicians navigate treatment options within regulatory guidelines while ensuring pediatric safety.

The move positions Wanbury to capture a significant portion of India?s Rs 861 crore Cold Preparation Liquid market, particularly in the pediatric segment. Coriminic CPM Drops provide targeted relief from allergic symptoms such as severe cold, blocked nose, and sneezing, aligning with rational prescribing practices and government safety advisories.

Wanbury?s initiative marks the first India-focused effort to reposition Chlorpheniramine in a safer, indication-driven format for children, consolidating the company?s presence in the fast-growing pediatric cold care segment.

The company continues to focus on delivering high-quality, affordable healthcare solutions across key therapeutic areas, including pediatrics.

Wanbury is engaged in the business of pharmaceutical and related activities, including research.

The company?s consolidated net profit zoomed 1197.1% to Rs 13.49 crore on 24.5% rise in revenue from operations to Rs 163.18 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News